In a recent issue of CHEST (March 2011), Tashkin et al 1 present results of a double-blind, placebo-controlled, two-arm trial of varenicline for smoking cessation in patients with COPD. The question arises: Why was a trial conducted in which varenicline was compared only with a placebo (and not with another active smoking cessation drug) in this patient group?
According to article 32 of the World Medical Association's Ethical Principles for Medical Research Involving Human Subjects, "the effectiveness of a new intervention must be tested against those of the best current proven intervention." 2 The use of a placebo is only acceptable in studies in which no current proven intervention exists. However, nicotine replacement therapy and bupropion were available interventions recommended by international evidence-based guidelines as fi rst-line pharmacologic treatments for smoking cessation in patients with respiratory disease. 3 For example, an earlier trial in patients with COPD, notably, conducted by Tashkin et al 4 as well, had shown that smokers who received bupropion for smoking cessation achieved higher continuous abstinence rates than smokers treated with placebo. Furthermore, two large-scale trials 5 , 6 had clearly shown the greater benefi t of varenicline compared with placebo and bupropion in the general smoking population-1 year before the current trial by Tashkin et al was initiated. The trial by Tashkin et al is the fi rst to investigate the effi cacy of varenicline in patients with COPD, but the authors do not provide compelling and scientifi cally sound methodologic reasons that justify the use of a placebo control instead of existing evidence-based smoking cessation medication. They only state that smokers with COPD have higher levels of nicotine dependence and are "more resistant to smoking cessation interventions" than smokers without COPD, but this is true for other subtypes of smokers as well, for example smokers with a lower socioeconomic background.
Two-arm placebo-controlled trials should no longer be conducted because they do not provide suffi cient information on the effectiveness and safety of a new smoking cessation drug in relation to existing drugs. Given the evidence base of available pharmacologic aids for smoking cessation, future trials with varenicline (or other drugs) that provide good reasons for using a placebo as a comparator should at least incorporate a third study arm in which the best alternative pharmacologic treatment of smoking cessation is administered. However, a search of international registers ( http :// apps . who . int / trialsearch ) shows that several trials are still recruiting smokers into two-arm placebo-controlled trials with varenicline (for example trials in patients with depression, schizophrenia, bipolar disorder, and HIV) and trials in smokers receiving alternative dosing schedules and varenicline for relapse prevention. Researchers, medical ethics committees, and regulatory authorities should keep in mind that the health of smokers in a placebo group is at stake. Smokers from the placebo group have a decreased chance of successful quitting, and each unsuccessful attempt increases the risk of smoking-related disease and reduced life expectancy, especially in a vulnerable group like patients with COPD. 
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Response
To the Editor:
With regard to our recently published article reporting the results of a randomized, controlled trial on the effects of varenicline (March 2011), 1 Kotz and van Schayck question the justifiability of placebo use as the only comparator in randomized controlled trials of pharmacotherapy for smoking cessation in patients with COPD. They go on to state that "The use of a placebo is only acceptable in studies in which no current proven intervention exists." What they fail to appreciate is that both the smokers with COPD who were allocated to the placebo and active arms of the varenicline trial received the benefi t of counseling for smoking cessation during weekly clinic visits over the 12-week double-blind treatment period and on seven subsequent clinic visits and fi ve telephone visits over the remainder of the 40-week follow-up period. Counseling is effective, and its effectiveness increases with intensity and total amount of counseling time according to the US Public Health Service Clinical Practice Guideline on treating tobacco use and dependence. 2 Thus, the patients treated with placebo were exposed to a level of counseling for smoking cessation that most likely exceeds that which smokers outside of the study would generally receive.
Very few previous studies of pharmacotherapy for smokers with COPD have been published. In one such study, as noted by Kotz and Schayck, smokers with COPD who had received bupropion achieved signifi cantly higher continuous abstinence rates than smokers treated with placebo at 3 and 6 months, 3 implying that the smokers treated with placebo in the varenicline COPD trial were deprived of an effective pharmacologic aid for smoking cessation as a positive control. However, the bupropion COPD trial, which included a follow-up period up to 1 year, failed to demonstrate a signifi cant difference between bupropion and placebo in continuous abstinence rates at the end of the follow-up period. Consequently, it has not been convincingly demonstrated that bupropion is an effective pharmacologic aid for smoking cessation and sustained abstinence in smokers with COPD. In the absence of evidence that alternative pharma cologic aids for smoking cessation have long-term effi cacy in smok ers with COPD, we believe that the use of a placebo arm in the varenicline COPD trial (in which all subjects received the benefi ts of counseling) was justifi ed in order to test the hypothesis that varenicline plus counseling is an effective treatment strategy for promoting long-term abstinence from smoking compared with counseling alone (ie, placebo medication plus counseling).
